Payment overview · 2025
General Payments
$714.84
6 reported records · 5 companies
Healthcare provider profile · identity verified
Stephen Frederick Oehme, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROCK HILL, SC · NPI 1861493496
Verified facts
What the public records show
CMS Open Payments records show Stephen Frederick Oehme, MD received $714.84 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.72 | 33.8% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $135.00 | 18.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.62 | 16.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $110.03 | 15.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $107.47 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.84 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $110.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $107.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 889 | 265 |
| Omeprazole | Omeprazole | 823 | 261 |
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 640 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 553 | 186 |
| Losartan Potassium | Losartan Potassium | 479 | 152 |
| Gabapentin | Gabapentin | 407 | 144 |
| Lisinopril | Lisinopril | 369 | 119 |
| Tramadol Hcl | Tramadol Hcl | 356 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 347 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 335 | 115 |
| Potassium Chloride | Potassium Chloride | 332 | 101 |
| Fluticasone Propionate | Fluticasone Propionate | 315 | 122 |
| Simvastatin | Simvastatin | 315 | 89 |
| Furosemide | Furosemide | 299 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 278 | 77 |
| Trazodone Hcl | Trazodone Hcl | 273 | 88 |
| Famotidine | Famotidine | 269 | 99 |
| Metformin Hcl | Metformin Hcl | 263 | 89 |
| Clonazepam | Clonazepam | 255 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 243 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 41 |
| Metformin Hcl Er | Metformin Hcl | 238 | 75 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 236 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 80 |
| Tizanidine Hcl | Tizanidine Hcl | 232 | 78 |
| Allopurinol | Allopurinol | 227 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 210 | 68 |
| Meloxicam | Meloxicam | 200 | 72 |
| Montelukast Sodium | Montelukast Sodium | 196 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 196 | 60 |
| Donepezil Hcl | Donepezil Hcl | 195 | 59 |
| Prednisone | Prednisone | 180 | 120 |
| Alprazolam | Alprazolam | 174 | 22 |
| Sertraline Hcl | Sertraline Hcl | 165 | 51 |
| Buspirone Hcl | Buspirone Hcl | 164 | 47 |
| Glipizide Er | Glipizide | 160 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 160 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 45 |
| Eliquis | Apixaban | 141 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 138 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 125 | 44 |
| Temazepam | Temazepam | 119 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 115 | 30 |
| Ozempic | Semaglutide | 114 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 42 |
| Amoxicillin | Amoxicillin | 101 | 73 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 41 |
| Azithromycin | Azithromycin | 97 | 89 |
| Alendronate Sodium | Alendronate Sodium | 96 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 24 |
| Fluconazole | Fluconazole | 84 | 41 |
| Ezetimibe | Ezetimibe | 83 | 30 |
| Pregabalin | Pregabalin | 82 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 17 |
| Carvedilol | Carvedilol | 80 | 27 |
| Lovastatin | Lovastatin | 76 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 63 |
| Lorazepam | Lorazepam | 68 | 13 |
| Spironolactone | Spironolactone | 65 | 20 |
| Finasteride | Finasteride | 64 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 19 |
| Estradiol | Estradiol | 60 | 20 |
| Valacyclovir | Valacyclovir Hcl | 59 | 32 |
| Glimepiride | Glimepiride | 58 | 17 |
| Mupirocin | Mupirocin | 58 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 31 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 55 | 12 |
| Diazepam | Diazepam | 55 | 15 |
| Cefuroxime | Cefuroxime Axetil | 54 | 52 |
| Telmisartan | Telmisartan | 52 | 15 |
| Azelastine Hcl | Azelastine Hcl | 51 | 18 |
| Glipizide | Glipizide | 51 | 14 |
| Lansoprazole | Lansoprazole | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 49 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 13 |
| Ketoconazole | Ketoconazole | 47 | 26 |
| Meclizine Hcl | Meclizine Hcl | 47 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 24 |
| Atenolol | Atenolol | 45 | 17 |
| Ibuprofen | Ibuprofen | 45 | 20 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 44 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 15 |
| Topiramate | Topiramate | 44 | 15 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Colchicine | Colchicine | 40 | 17 |
| Primidone | Primidone | 40 | 14 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Naproxen | Naproxen | 39 | 12 |
| Torsemide | Torsemide | 39 | 17 |
| Verapamil Er | Verapamil Hcl | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 37 | 15 |
| Promethazine Hcl | Promethazine Hcl | 37 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | 13 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Nystatin | Nystatin | 34 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Cephalexin | Cephalexin | 33 | 29 |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Linzess | Linaclotide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 18 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 24 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 11 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 14 |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.84 · 6 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, Da Vinci Surgical System, FARXIGA, Ozempic, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error